Claim: Somatostatin receptor type 2 is a protein associated to possible alternatives to current pituitary tumor treatment  and is particularly effective against TSHomas.
Evidence: Somatostatin receptor type 2 is a protein that in humans is encoded by the SSTR2 gene. The binding of synthetic somatostatin hormones such as octreotide to receptors has been seen to reduce the production of hormones and is now being considered for use in the treatment of some pituitary tumors. One group suggests that the treatment method would be particularly effective against thyrotropin-secreting pituitary adenomas (TSHomas), though further inquiries and clinical trials are needed.